MedTrace Logo

Study of Pentasa® for Reducing Residual Systemic Immune Activation in Treated HIV Infection

NCT03399903 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2020-03-04

No results posted yet for this study

Summary

An open label study will be performed on 80 people with HIV infection who are maintained on effective treatment with antiretroviral drugs.

Conditions

Interventions

DRUG

Pentasa vs Align

We will examine the safety and possible effectiveness of Pentasa® and Align in reducing markers of immune activation believed to be important reflectors of risk for cardiovascular disease and ongoing immune damage in people with chronic treated HIV-1 infection.

Sponsors & Collaborators

  • HIV Immunotherapeutics Institute

    collaborator OTHER

  • AIDS Healthcare Foundation

    lead OTHER

Principal Investigators

  • Otto O Yang, MD · AIDS Healthcare Foundation - HIV Immunotherapeutics Institute

  • Peter Anton, MD · AIDS Healthcare Foundation - HIV Immunotherapeutics Institute

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-05-01
Primary Completion
2019-03-22
Completion
2019-03-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03399903 on ClinicalTrials.gov